The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

BROMCRESOL GREEN     2,6-dibromo-4-[9-(3,5- dibromo-4-hydroxy-2...

Synonyms: CHEMBL145704, NSC-7817, NSC7817, B0381_SIAL, KB-48467, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of BROMCRESOL GREEN


Psychiatry related information on BROMCRESOL GREEN

  • The bromcresol green method has been improved considerably by shortening the reaction time before the absorbance is measured, as is described here [5].
  • Within the 12-month observation time study patients with pTa G2 and pT1 G2 tumors showed a recurrence rate of 33%, comparable to that in a local historical control group of patients with equal stage and grade who were treated with adjuvant BCG [6].
  • Shortly after Morales' original report, several phase II trials confirmed the effectiveness of intravesical bacillus Calmette-Guérin (BCG) in superficial bladder cancer therapy [7].
  • This article reviews the life experiences of this pioneer bioscientist, the current status of BCG in preventing tuberculosis, and the potential of BCG in immunotherapy for cancer [8].

High impact information on BROMCRESOL GREEN


Chemical compound and disease context of BROMCRESOL GREEN


Biological context of BROMCRESOL GREEN


Anatomical context of BROMCRESOL GREEN


Associations of BROMCRESOL GREEN with other chemical compounds


Gene context of BROMCRESOL GREEN


Analytical, diagnostic and therapeutic context of BROMCRESOL GREEN


  1. Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Shirai, T., Yamaguchi, H., Ito, H., Todd, C.W., Wallace, R.B. Nature (1985) [Pubmed]
  2. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Aldovini, A., Young, R.A. Nature (1991) [Pubmed]
  3. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Yoshida, H., Hamano, S., Senaldi, G., Covey, T., Faggioni, R., Mu, S., Xia, M., Wakeham, A.C., Nishina, H., Potter, J., Saris, C.J., Mak, T.W. Immunity (2001) [Pubmed]
  4. Skeletal and soft tissue sarcomas. Treatment with adjuvant immunotherapy. Townsend, C.M., Eilber, F.R., Morton, D.L. JAMA (1976) [Pubmed]
  5. Improved continuous-flow (SMAC) determination of serum albumin. Cederblad, G., Hickey, B.E., Hollender, A., Akerlund, G. Clin. Chem. (1978) [Pubmed]
  6. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract. Elsässer-Beile, U., Leiber, C., Wolf, P., Lucht, M., Mengs, U., Wetterauer, U. J. Urol. (2005) [Pubmed]
  7. BCG in superficial bladder cancer: a review of phase III European trials. Pagano, F., Bassi, P., Milani, C., Piazza, N., Meneghini, A., Garbeglio, A. Eur. Urol. (1992) [Pubmed]
  8. Albert Léon Charles Calmette (1863-1933) and the antituberculous BCG vaccination. Chung, K.T., Biggers, C.J. Perspect. Biol. Med. (2001) [Pubmed]
  9. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Langermann, S., Palaszynski, S., Sadziene, A., Stover, C.K., Koenig, S. Nature (1994) [Pubmed]
  10. Defective NK cell activity and Th1 response in IL-18-deficient mice. Takeda, K., Tsutsui, H., Yoshimoto, T., Adachi, O., Yoshida, N., Kishimoto, T., Okamura, H., Nakanishi, K., Akira, S. Immunity (1998) [Pubmed]
  11. Mycobacteria target DC-SIGN to suppress dendritic cell function. Geijtenbeek, T.B., Van Vliet, S.J., Koppel, E.A., Sanchez-Hernandez, M., Vandenbroucke-Grauls, C.M., Appelmelk, B., Van Kooyk, Y. J. Exp. Med. (2003) [Pubmed]
  12. Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guérin (BCG) suppresses allergen-induced airway eosinophilia. Erb, K.J., Holloway, J.W., Sobeck, A., Moll, H., Le Gros, G. J. Exp. Med. (1998) [Pubmed]
  13. Mycobacterial virulence. Virulent strains of Mycobacteria tuberculosis have faster in vivo doubling times and are better equipped to resist growth-inhibiting functions of macrophages in the presence and absence of specific immunity. North, R.J., Izzo, A.A. J. Exp. Med. (1993) [Pubmed]
  14. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy. Vaage, J. Cancer Res. (1983) [Pubmed]
  15. Bacillus Calmette-Guérin enhancement of colony-stimulating activity and myeloid colony formation following administration of cyclophosphamide. Ladisch, S., Reaman, G.H., Poplack, D.G. Cancer Res. (1979) [Pubmed]
  16. Immunotherapeutic response of concanavalin A-bound L1210 vaccine enhanced by a streptococcal immunopotentiator, OK-432. Kataoka, T., Oh-hashi, F., Sakurai, Y. Cancer Res. (1979) [Pubmed]
  17. Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guérin. Molloy, A., Laochumroonvorapong, P., Kaplan, G. J. Exp. Med. (1994) [Pubmed]
  18. Origin and kinetics of pulmonary macrophages during an inflammatory reaction induced by intravenous administration of heat-killed bacillus Calmette-Guérin. Blussé van Oud Alblas, A., van der Linden-Schrever, B., van Furth, R. J. Exp. Med. (1981) [Pubmed]
  19. Evidence inconsistent with a role for the Bcg gene (Nramp1) in resistance of mice to infection with virulent Mycobacterium tuberculosis. Medina, E., North, R.J. J. Exp. Med. (1996) [Pubmed]
  20. Down-regulation of mannosyl receptor-mediated endocytosis and antigen F4/80 in bacillus Calmette-Guérin-activated mouse macrophages. Role of T lymphocytes and lymphokines. Ezekowitz, R.A., Gordon, S. J. Exp. Med. (1982) [Pubmed]
  21. Immunoreactivity of a 70 kD protein purified from Mycobacterium bovis Bacillus Calmette-Guerin by monoclonal antibody affinity chromatography. Britton, W.J., Hellqvist, L., Basten, A., Inglis, A.S. J. Exp. Med. (1986) [Pubmed]
  22. Bacillus Calmette-Guérin-activated murine macrophages kill syngeneic melanoma cells under strict anaerobic conditions. Freedman, V.H., Gorrell, T.E., Nathan, C.F., Copeland, C.S., Silverstein, S.C. J. Exp. Med. (1984) [Pubmed]
  23. Recognition and destruction of Bacillus Calmette-Guerin-infected human monocytes. Molloy, A., Meyn, P.A., Smith, K.D., Kaplan, G. J. Exp. Med. (1993) [Pubmed]
  24. Macrophages elicited with heat-killed bacillus Calomette-Guérin protect C57BL/6J mice against a syngeneic melanoma. Freedman, V.H., Calvelli, T.A., Silagi, S., Silverstein, S.C. J. Exp. Med. (1980) [Pubmed]
  25. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. Inaba, K., Inaba, M., Naito, M., Steinman, R.M. J. Exp. Med. (1993) [Pubmed]
  26. Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guérin and subsequent challenge with lipopolysaccharide. Kamijo, R., Le, J., Shapiro, D., Havell, E.A., Huang, S., Aguet, M., Bosland, M., Vilcek, J. J. Exp. Med. (1993) [Pubmed]
  27. Apoprotein E is synthesized and secreted by resident and thioglycollate-elicited macrophages but not by pyran copolymer- or bacillus Calmette-Guerin-activated macrophages. Werb, Z., Chin, J.R. J. Exp. Med. (1983) [Pubmed]
  28. Binding of bacillus Calmette-Guérin-activated macrophages to tumor targets. Selective inhibition by membrane preparations from homologous and heterologous neoplastic cells. Marino, P.A., Whisnant, C.C., Adams, D.O. J. Exp. Med. (1981) [Pubmed]
  29. Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. Lum, B.L., Torti, F.M. J. Natl. Cancer Inst. (1991) [Pubmed]
  30. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Livingston, P.O., Natoli, E.J., Calves, M.J., Stockert, E., Oettgen, H.F., Old, L.J. Proc. Natl. Acad. Sci. U.S.A. (1987) [Pubmed]
  31. A macrophage invasion mechanism for mycobacteria implicating the extracellular domain of CD43. Fratazzi, C., Manjunath, N., Arbeit, R.D., Carini, C., Gerken, T.A., Ardman, B., Remold-O'Donnell, E., Remold, H.G. J. Exp. Med. (2000) [Pubmed]
  32. The beta-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteria. Yadav, M., Schorey, J.S. Blood (2006) [Pubmed]
  33. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine. Chung, M.A., Luo, Y., O'Donnell, M., Rodriguez, C., Heber, W., Sharma, S., Chang, H.R. Cancer Res. (2003) [Pubmed]
  34. Involvement of IFN-gamma in Bacillus Calmette-Guérin-induced but not in tumor-induced sensitization to TNF-induced lethality. Cauwels, A., Brouckaert, P., Grooten, J., Huang, S., Aguet, M., Fiers, W. J. Immunol. (1995) [Pubmed]
  35. Vaccination against tuberculosis by DNA injection. Tascon, R.E., Colston, M.J., Ragno, S., Stavropoulos, E., Gregory, D., Lowrie, D.B. Nat. Med. (1996) [Pubmed]
  36. Regression of tumors in guinea pigs after treatment with synthetic muramyl dipeptides and trehalose dimycolate. McLaughlin, C.A., Schwartzman, S.M., Horner, B.L., Jones, G.H., Moffatt, J.G., Nestor, J.J., Tegg, D. Science (1980) [Pubmed]
  37. Host response to mycobacterial infection in the alcoholic rat. Mendenhall, C.L., Grossman, C.J., Roselle, G.A., Ghosn, S., Gartside, P.S., Rouster, S.D., Chalasani, P.V., Schmitt, G., Martin, K., Lamping, K. Gastroenterology (1990) [Pubmed]
  38. Systemic therapy for metastatic breast cancer. Haskell, C.M., Sparks, F.C., Graze, P.R., Korenman, S.G. Ann. Intern. Med. (1977) [Pubmed]
WikiGenes - Universities